AngioDynamics' NanoKnife FDA clearance boosts its potential in cancer treatment. Read why ANGO stock is a buy with its growth ...
13d
AngioDynamics Inc (ANGO) reports a robust 9% revenue growth, driven by MedTech and mechanical thrombectomy segments, while ...
AngioDynamics, Inc. (ANGO), a New York-based medical technology company Monday announced the publication of results from the Acute ...
Angiodynamics, Inc. ( (ANGO) ) has released its Q2 earnings. Here is a breakdown of the information Angiodynamics, Inc. presented to its ...
AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.05 per share a year ago. These figures ...
Moody National Bank Trust Division increased its position in AngioDynamics, Inc. (NASDAQ:ANGO – Free Report) by 70.2% in the ...
Q2 2025 Earnings Conference Call January 8, 2025 8:00 AM ETCompany ParticipantsJim Clemmer - President and Chief ...
The Federal Capital Territory Internal Revenue Service, FCT-IRS says January 31 is the deadline for employers in the region ...
AngioDynamics (NASDAQ:ANGO – Free Report) had its price objective increased by HC Wainwright from $14.00 to $15.00 in a research note released on Friday,Benzinga reports. They currently have a buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback